Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

THEY'RE ADVERTISED AS OZEMPIC OR WEGOVY. 12;40;15;00 THE GENERIC NAME IS SEMAGLUTIDE, THESE ARE IN A CLASS OF MEDICATIONS ...

The company behind blockbuster obesity treatment Wegovy and diabetes drug Ozempic is busy developing ... body weight loss of 9.7% on the smallest dose after 20 weeks, rising to 22% on the highest ...

Wegovy is an injectable medication that contains semaglutide, the same active ingredient as Ozempic, but in a slightly higher dose. However, unlike Ozempic, Wegovy is FDA approved for weight ...

The FDA and EMA have both accepted Biogen’s applications for a higher dose regimen of Spinraza (nusinerse) for spinal muscular atrophy (SMA). According to the company, the regimen includes a faster ...

The starting dose of Ozempic is 0.25 mg once a week for the first 4 weeks [8]. At week 5, the dose will be increased to 0.5 mg once a week. What are the possible long-term considerations you need ...